Nerandomilast

Top 5 IPF articles of 2024 include oxygen therapy's impact on fibrosing ILD, delayed diagnoses linked to worse outcomes, nerandomilast's success in FIBRONEER-IPF trial, diabetes' effect on pulmonary fibrosis, and increased macrophage research since 2020.

Refoxy Pharma secures $9.58 million to develop IPF drug RP-01 targeting FOXO3. Boehringer Ingelheim plans NDA submission for nerandomilast. Insilico's ISM001-055 and Endeavor's ENV-101 show disease improvement. Vicore's buloxibutid and BMS' BMS-986278 also chart progress. Pliant's bexotegrast mitigates chronic cough in IPF. IPOs and partnerships fuel IPF therapeutic field.

Bridge Biotherapeutics, Daewoong, and Ildong Pharmaceutical lead in IPF treatment development, with Bridge's BBT-877 in Phase 2 trials targeting autotaxin. Daewoong's Versiporocin aims to reduce PRS protein action, while Ildong's IL1512 targets CXCR7. Hanmi's HM15211, initially for MASH, shows IPF efficacy. Boehringer Ingelheim's Nerandomilast met primary trial endpoints, but side effects are a concern.

Boehringer Ingelheim’s Phase 3 trial of nerandomilast for idiopathic pulmonary fibrosis (IPF) met its primary goal, showing improved lung function or prevention of decline over a year. The trial enrolled 1,177 patients globally, with full data to be presented in 2025. Boehringer plans to seek FDA approval for nerandomilast, which targets phosphodiesterase 4B to reduce inflammation and scarring in IPF and other interstitial lung diseases.

Boehringer Ingelheim and Insilico Medicine reported positive data from their idiopathic pulmonary fibrosis (IPF) drug trials, indicating potential to stop or reverse lung function decline. Boehringer's nerandomilast showed significant FVC improvement in a Phase III trial, while Insilico's ISM001-055 demonstrated dose-dependent FVC improvement in a Phase IIa trial. Both companies await further data and regulatory feedback.

Insilico Medicine's AI-designed drug ISM001-055 shows positive Phase 2a results for idiopathic pulmonary fibrosis (IPF), with dose-dependent improvement in forced vital capacity (FVC). The drug targets TNIK enzyme, identified via generative AI, and is set for further Phase 2b studies. Competitors include Boehringer Ingelheim's nerandomilast and Pliant Therapeutics' bexotegrast, both showing promising results in IPF treatment.

Boehringer Ingelheim's investigational drug, nerandomilast, met the primary endpoint in the phase 3 FIBRONEER-IPF trial, marking the first success in a decade for treating idiopathic pulmonary fibrosis (IPF). The trial showed improved lung function based on absolute change in forced vital capacity (FVC) at week 52 compared to placebo. Boehringer Ingelheim plans to submit a new drug application for nerandomilast, which could offer a novel treatment option for IPF, currently limited to nintedanib and pirfenidone.

Novartis' Kisqali gets FDA approval for early-stage breast cancer; GSK's vaccines for RSV and shingles co-administered effectively; Novo Nordisk partners with NanoVation for genetic therapies; AstraZeneca's Mene Pangalos joins Omega Funds; Serán Biosciences secures $200M for new facility; Boehringer Ingelheim's nerandomilast shows success in Phase 3 IPF trial.

Boehringer Ingelheim's nerandomilast met primary endpoint in Phase III FIBRONEER-IPF study, significantly improving lung function in IPF patients. The drug targets PDE4B enzyme to exert anti-fibrotic and anti-inflammatory effects. Boehringer plans to use study results for FDA and global regulatory submissions, with full data expected in H1 2025.